You are here: Industry Insights > NICE

News List

NICE recommends Adcetris (brentuximab vedotin) for treatment of rare lymphoma europeanpharmaceuticalreview
July 14, 2020
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
NICE does not recommend Novartis’ siponimod for secondary progressive MS europeanpharmaceuticalreview
June 30, 2020
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
NICE rejects Novartis' Mayzent for secondary progressive MS pharmatimes
June 29, 2020
NICE has turned down NHS funding in preliminary guidelines for use of Novatis' Mayzent (siponimod) as a treatment for secondary progressive multiple sclerosis (SPMS) with evidence of active disease.
NICE sticks to Zytiga rejection pharmatimes
June 29, 2020
NICE will not be recommending Janssen's Zytiga (abiraterone acetate) with prednisone or prednisolone plus androgen deprivation therapy (ADT), within its marketing authorisation , for treating newly diagnosed high-risk metastatic ...
Final NICE green light for Janssen's Stelara in UC pharmatimes
June 18, 2020
The National Institute for Health and Care Excellence (NICE) has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to treat ulcerative colitis.
NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC europeanpharmaceuticalreview
June 17, 2020
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
NICE rejects Sanofi's Cablivi in draft guidelines pharmatimes
June 16, 2020
NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP).
NICE backs Rozlytrek for subset of NSCLC patients pharmatimes
June 16, 2020
NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment option for ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Final NHS green light for Roche's Kadcyla pharmatimes
June 11, 2020
NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer.
NICE rejects Sanofi's Sarclisa in preliminary guidelines pharmatimes
June 09, 2020
NICE has published initial guidelines rejecting NHS use of a therapy combination containing Sanofi's Sarclisa (isatuximab) to treat multiple myeloma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page